tiprankstipranks
Advertisement
Advertisement
Avalo Completes Enrollment for Phase 2 LOTUS Trial
PremiumCompany AnnouncementsAvalo Completes Enrollment for Phase 2 LOTUS Trial
4M ago
Avalo Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Avalo Therapeutics Reports Q3 2025 Financial Results
5M ago
Avalo Therapeutics reports Q3 EPS ($2.19), consensus ($1.64)
Premium
The Fly
Avalo Therapeutics reports Q3 EPS ($2.19), consensus ($1.64)
5M ago
Avalo Therapeutics management to meet with Piper Sandler
PremiumThe FlyAvalo Therapeutics management to meet with Piper Sandler
6M ago
Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation
Premium
Company Announcements
Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation
6M ago
Avalo Therapeutics Strengthens Leadership with Key Appointments
Premium
Company Announcements
Avalo Therapeutics Strengthens Leadership with Key Appointments
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100